Verisante Technology, Inc. Announces Exclusive Distribution Agreement with BO-Pharma BV
News Sep 20, 2012
Verisante Technology, Inc. announced that the Company has entered into an exclusive agreement with BO-Pharma BV to distribute Verisante Aura™ in Belgium, the Netherlands and Luxemburg ("Benelux").
"BO-Pharma is the largest independent distributor of medical devices in the Benelux region," said Thomas Braun, President & CEO of Verisante. "With the Benelux market outselling the UK and Germany in some dermatological and skin care devices, our partnership with BO-Pharma provides us a strong foothold in this important region. BO-Pharma will not only distribute Aura™, but can also support technical training and servicing in the region."
BO-Pharma and its affiliate, Bo-Esthetics, currently distribute medical devices for skin care treatments, in addition to other devices for use in dermatological practices for a variety of other medical applications. Bo-Esthetics is a leading dermatology distributor in Benelux, distributing the world's top dermatology brands. Aura™ is a natural addition to the Company's existing product line.
"Impressive clinical study results show that Aura™, through speed and accuracy, is a device that can revolutionize the way skin cancer is diagnosed," said Dr. Henk-Peter Oonk, CEO of BO-Pharma. "The Netherlands has historically been very quick to adopt new, disruptive medical technologies, and we are confident this trend will continue with Aura™."
Last year, Aura™ received the Conformite Europeenne (CE) Mark approval, which is recognized by all the 27 Member States of the EU, including Benelux, which has a total population of over 30 million people, and approximately 1,000 dermatologists serving the region. The CE Mark allows the Company to sell Aura™ in Europe, a $78 billion medical device market.
Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.
Flow Chemistry and Continuous Processing Conference
Apr 08 - Apr 09, 2019